Confidence
in drug
delivery2-5

Preferred by patients2-4

Over 80% of patients and HCPs preferred to use FlexTouch® vs. SoloSTAR®† or KwikPen®‡2–4

*After the dose display has returned to zero, the needle should be kept under the skin for at least 6 seconds to ensure the full dose is delivered. †Glargine 100 units/ml ‡In two usability studies, n=120 and n=160.2,3

Important Note: The content of this website is not intended to be a substitute for professional medical advice, diagnosis or treatment. Do not disregard or delay in seeking a doctor’s advice because of the information provided on this website.

Who we are

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,600 people in 75 countries and markets its products in more than 180 countries.